Oruka Therapeutics (ORKA) Shares Outstanding (Weighted Average) (2010 - 2026)

Oruka Therapeutics has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $55.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 32.37% year-over-year to $55.2 million; the trailing twelve-month figure through Mar 2026 stood at $55.2 million (up 32.37% YoY), and the FY2025 full-year result was $1.1 million, down 93.65% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $55.2 million, up from $1.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $55.2 million in Q1 2026, with the low at $477.0 in Q3 2024.
• Average Shares Outstanding (Weighted Average) over 5 years is $19.6 million, with a median of $14.4 million recorded in 2022.
• Year-over-year, Shares Outstanding (Weighted Average) tumbled 100.0% in 2024 and soared 9238277.15% in 2025.
• Tracing ORKA's Shares Outstanding (Weighted Average) over 5 years: stood at $14.4 million in 2022, then advanced by 0.04% to $14.4 million in 2023, then advanced by 16.46% to $16.8 million in 2024, then slumped by 93.65% to $1.1 million in 2025, then jumped by 5072.42% to $55.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $55.2 million (Q1 2026), $1.1 million (Q4 2025), and $44.1 million (Q3 2025), per Business Quant data.

Peer Comparison